^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

COMPANY:
Previse

i
Other names: Previse | Capsulomics
Related tests:
Evidence

News

8ms
Previse wins $1.8M NIH grant to help advance esophageal cancer risk PCR test (Genomeweb)
"Previse said on Thursday that it has been awarded a $1.8 million grant from the National Institutes of Health to support additional clinical testing of Esopredict, the company's recently launched laboratory-developed real-time PCR test for esophageal cancer risk."
Grant
|
Esopredict™ test
1year
Previse presents data from two studies at Digestive Disease Week 2023 on new tests to detect risk of esophageal cancer (Previse Press Release)
"Previse...announced details on Monday, May 8, of two studies presented during Digestive Disease Week® 2023, held May 6-9 in Chicago. Both analyses clinically validate use of biomarkers to detect and assess risk of esophageal cancer developing in patients with Barrett’s esophagus."
Clinical data
|
Esopredict™ test
1year
PREVISE CLOSES $3M SEED TO TACKLE EARLY CANCER DETECTION AND LAUNCHES COMPANY’S FIRST ESOPHAGEAL CANCER PROGNOSTIC TEST (PRNewswire)
"Previse, formerly known as Capsulomics, Inc., announced that the company has closed a $3M seed round and launched its first laboratory-developed test, Esopredict™....In addition to launching Esopredict™, Previse also raised a $3M seed round, with participation from TEDCO, Wexford Science and Technology, Riptide Ventures, Gaingels, and numerous angel investors."
Financing • Launch
|
Esopredict™ test